

CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

March 26, 2004

Date

Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Rolf A. Brekken

Serial No.: 10/738,404

Filing Date: December 17, 2003

For: ANTI-VEGF ANTIBODY PRODRUG

METHODS (As Amended)

Group Art Unit: 1642

Examiner: Yaen, C.

Atty. Dkt. No.: 3999.002587

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the documents listed on the enclosed Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the

receipt of a first Official Action reflecting an examination on the merits and hence is timely filed

in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be due in connection

herewith. Even if an Official Action had been issued in the last few days, no fees would be

required in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed

in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent

office in a counterpart foreign application. The listed documents were each cited in an Official

Action on the merits in a co-pending application of one of the present inventors, Serial

No. 09/766,491 (Attorney Docket No. 3999.002782), mailed from the P.T.O. on January 13,

2004, less than three months before the filing of the present statement, and could not have been

submitted before receipt.

No fees should be due in connection with the filing of this Supplemental Information

Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed

necessary for any reason relating to these materials, the Examiner should contact the undersigned

representative to discuss deduction from Williams, Morgan & Amerson Deposit Account

No. 50-0786/3999.002587.

Respectfully submitted,

Williams, Morgan & Amerson, P.C.

Customer No. 23720

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458

Agent for Applicants

(713) 934-4079

Date: March 26, 2004

10333 Richmond, Suite 1100

Houston, Texas, 77042

2

Form PTO-1449 (modified)				Atty. Docket No. 3999.002587			Serial No. 10/738,404		
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT					Applicant Thorpe and Brekken				
(Use several sheets if necessary)				Filing Date: December 17, 2003			Group: 1642		
U.S. Patent Documents See Page				Foreign Patent Documents See Page			Other Art See Page 1		
			U.S. Pate	nt D	ocuments	<u> </u>			
Exam. Init.	Ref. Des.	Document Number	Dat	e	Name	Clas	s Sub Class	Filing Date of App.	
		Fo	oreign Pa	tent	Documer	nts			
Exam. Init.	Ref. Des.	Document Number	Date)	Country	Class	Sub Class	Translation Yes/No	
	Other A	Art (Includin	g Author,	Title	e, Date Pe	ertinen	t Pages	s, Etc.)	
Exam. Init.	Ref. Des.	Citation							
	C96	Ezzell et al., "Cancer "Vaccines": An Idea Whose Time Has come?," J. NIH Research, 7:46-49, 1995.							
	C97	Skolnick et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era," TIBTECH, 18:34-39, 2000.							

EX	AN	IIN	ER:
----	----	-----	-----

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.